0001) and of C5a (20.8ng/ml [5.6-27.5] vs 12.7ng/ml [3.2-24.6]; P=0.004), which decreased three months after delivery (SC5b9 190ng/ml [83-446] vs 160ng/ml [107-219]; C5a 9.28ng/ml [2.3-21.6] vs 10.7ng/ml [2.5-21.2]). A significantly higher frequency of genetic variants involving complement regulatory genes was also observed (52.6% vs 15.8%;…[Read more]

The ongoing clinical trials will provide clearer information on efficacy, strength and safety of these molecules. The purpose of this review is to analyze the available evidence and future prospects of SGLT2 inhibitors, which could be widely used in nephrology clinical practice.Early in 2020, racehorse doping cases revolved around the…[Read more]

There are currently three anti-interleukin-5 (IL-5) pathway-directed therapies mepolizumab, reslizumab, and benralizumab. Of these, benralizumab was most recently approved. Benralizumab is administered every 8weeks after an initial 3 doses given every 4weeks, whereas mepolizumab and reslizumab are administered every 4weeks. This convenience in…[Read more]

From the included studies, 12 products were identified for wounds of different etiologies, with the most frequent being the alcohol-free barrier film and zinc oxide.

To date, the level of evidence is low. It is necessary to develop more robust research that improves the quality of the literature available for treating people with…[Read more]